Emerging drugs for Duchenne muscular dystrophy

Author： Malik Vinod Rodino-Klapac Louise R. Mendell Jerry R

ISSN： 1472-8214

Source： Expert Opinion on Emerging Drugs, Vol.17, Iss.2, 2012-06, pp. : 261-277

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pathophysiology and Therapy of Cardiac Dysfunction in Duchenne Muscular Dystrophy

By Judge Daniel P. Kass David A. Thompson W. Reid Wagner Kathryn R.

American Journal of Cardiovascular Drugs, Vol. 11, Iss. 5, 2011-10 ,pp. : 287-294

Adis International

Access to resources Recommend Favorite

Duchenne muscular dystrophy drug discovery – the application of utrophin promoter activation screening

By Moorwood Catherine Khurana Tejvir S

Expert Opinion on Drug Discovery, Vol. 8, Iss. 5, 2013-06 ,pp. : 569-581

Informa Healthcare

Access to resources Recommend Favorite

Deflazacort helps to maintain both muscle and pulmonary function in Duchenne muscular dystrophy

Inpharma, Vol. 1, Iss. 1275, 2001-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Personalised Genetic Intervention for Duchenne Muscular Dystrophy: Antisense Oligomers and Exon Skipping

Current Molecular Pharmacology, Vol. 2, Iss. 1, 2009-01 ,pp. : 110-121

Bentham Science Publishers

Access to resources Recommend Favorite

Splice Modification to Restore Functional Dystrophin Synthesis in Duchenne Muscular Dystrophy

Current Pharmaceutical Design, Vol. 16, Iss. 8, 2010-03 ,pp. : 988-1001

Bentham Science Publishers

Access to resources Recommend Favorite